BioLoomics Raises $8.7 Million Seed Round to Develop Target Degrading Antibodies

BOULDER, Colo.–(BUSINESS WIRE)–BioLoomics, the company pioneering directed evolution of target degrading antibodies using human cells, today announced it has raised $8.7 million in seed financing to advance its proprietary platform technology and antibody degrader programs. The round was led by Innovation Endeavors, with participation from Horizons Ventures, TechU Ventures, Boom Capital Ventures, Hummingbird Nomads Fund, Cooley GC&H, BoxOne Ventures and Viswa Colluru (Founder of Enveda).
Click here to view original post